E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial by Brigid O’Brien et al.
O’Brien et al. Tobacco Induced Diseases  (2015) 13:5 
DOI 10.1186/s12971-015-0030-2RESEARCH Open AccessE-cigarettes versus NRT for smoking reduction or
cessation in people with mental illness: secondary
analysis of data from the ASCEND trial
Brigid O’Brien, Oliver Knight-West, Natalie Walker*, Varsha Parag and Christopher BullenAbstract
Background: People with mental illness have higher rates of smoking than the general population and are at
greater risk of smoking-related death and disability. In smokers from the general population, electronic cigarettes
(e-cigarettes) have been shown to have a similar effect on quit rates as nicotine replacement therapy, but little is
known about their effect in smokers with mental illness.
Methods: Secondary analysis of data from the ASCEND trial involving 657 dependent adult smokers motivated to
quit, randomised to 16 mg nicotine e-cigarette, 21 mg nicotine patch, or 0 mg nicotine e-cigarette, with minimal
behavioural support. Using self-reported medication use and the Anatomical Therapeutic Chemical Classification
System, we identified 86 participants with mental illness and analysed their cessation and smoking reduction outcomes.
Results: For e-cigarettes alone, and all interventions pooled, there was no statistically significant difference in
biochemically verified quit rates at six months between participants with and without mental illness, nor in smoking
reduction, adverse events, treatment compliance, or acceptability. Rates of relapse to smoking were higher in
participants with mental illness. Among this group, differences between treatments were not statistically significant for
cessation (patch 14% [5/35], 16 mg e-cigarette 5% [2/39], 0 mg e-cigarette 0% [0/12], p = 0.245), adverse events or relapse
rates. However, e-cigarette users had higher levels of smoking reduction, treatment compliance, and acceptability.
Conclusions: The use of e-cigarettes for quitting appears to be equally effective, safe, and acceptable for people with
and without mental illness. For people with mental illness, e-cigarettes may be as effective and safe as patches, yet more
acceptable, and associated with greater smoking reduction.
Trial registration: Australian New Zealand Clinical trials Registry, number: ACTRN12610000866000.
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People affected by mental illness suffer excess morbidity
and mortality, with much of this disparity attributable to
cigarette smoking [1,2]. Such people are more cigarette
dependent, smoke more heavily [3,4], are less likely to
quit [4,5] and have a smoking prevalence several times
higher than those without mental illness [6]. Because
mental illness is common, affecting around a quarter of
people in any year in developed countries [7-9], smoking
in this population accounts for a large proportion of the
smoking-related disease burden and associated economic* Correspondence: n.walker@auckland.ac.nz
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unless otherwise stated.costs for health systems [10]. Reducing smoking rates in
people with mental illness is a public health priority.
People with mental illness are motivated to quit smok-
ing [4,11], but comparatively few data exist on the effi-
cacy of standard cessation interventions when used by
this population because they are routinely excluded from
clinical trials. The available evidence suggests bupropion
is effective, but it is unclear for varenicline and mixed
for nicotine replacement treatment (NRT) [2,12-17].
Despite a reduction in smoking prevalence across the
general population of most developed countries, there
has been little progress in boosting successful quit rates
among smokers with mental illness [7,18,19]. An urgent
need exists to increase the availability of cessation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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levels of cigarette addiction in this population [18].
Electronic cigarettes (e-cigarettes) are nicotine delivery
devices that have promise for smoking cessation: two
published randomised controlled trials (RCTs) involving
first generation e-cigarettes with low nicotine delivery
among general populations of smokers suggest modest
effectiveness, similar to nicotine patches with minimal
behavioural support [20,21]. A third trial involving
‘second generation’ e-cigarettes also supports these find-
ings [22]. Little is known about e-cigarette use in people
with mental illness. Only six studies have been reported
to date: a small (n = 14) uncontrolled pilot study in
patients with schizophrenia [23], three case reports of
patients (n = 1-2) with affective or anxiety disorders
[24-26], a US population-based survey (n = 10,041) [27],
and a recently published cohort study of 956 smokers
with severe mental illness participating in a smoking
cessation trial that did not involve e-cigarettes [28].
The latter study found that 11% of participants used
an e-cigarette during the study, and concluded that
e-cigarette use was not associated with changes in smok-
ing behaviour. However, it is not possible to draw such
firm conclusions from the data because people who ‘used’
an e-cigarette once and never again were not differenti-
ated from those who used them frequently and for sev-
eral months. The other studies suggested e-cigarettes
have cessation and harm reduction potential for people
with mental illness, including in those who were not mo-
tivated to quit, or who had previously tried to quit with
NRT but failed. The latter finding raises the possibility
that e-cigarettes might have an advantage over NRT
through their ability, over and above nicotine delivery, to
provide a coping mechanism for conditioned smoking
cues by replacing some of the rituals associated with
smoking gestures [23].
In order to investigate the above hypothesis we exam-
ined data from the largest randomised controlled trial of
e-cigarettes to date, the ASCEND trial, focussing on
participants who stated they were taking mental illness-
related medications, and therefore likely to have a men-
tal illness. We hypothesised that 1) nicotine patches and
e-cigarettes, individually and collectively, are equally as
effective, safe and acceptable for smoking cessation and
reduction for people with or without mental illness, and
that 2) e-cigarettes are more effective and acceptable
than nicotine patches for smoking cessation and reduc-
tion in people with mental illness.
Methods
The ASCEND trial protocol and main findings have
been described in detail elsewhere [21,29]. In brief,
657 dependent smokers aged ≥18 years, who were
motivated to quit, were recruited from the community inAuckland, New Zealand (NZ), and randomised in a 4:4:1
ratio to 16 mg nicotine e-cigarettes (ad libitum use),
21 mg nicotine patches (one daily) or 0 mg e-cigarettes
(ad libitum use), from one week before until 12 weeks
after the nominated quit day. Low intensity behavioural
support was offered via voluntary telephone counselling.
Smokers with poorly controlled psychiatric disorders or
chemical dependency other than nicotine were excluded.
The Northern X Regional Ethics Committee of New
Zealand approved the study (Number NTX/10/11/111);
the Standing Committee on Therapeutic Trials approved
the nicotine electronic cigarettes for research. All study
procedures were conducted in accordance with the
Declaration of Helsinki.
Participants were assessed by telephone at baseline,
quit date (one week post-baseline), one, three and six
months post quit-date. Concomitant medication use was
assessed at each time-point. The Anatomical Thera-
peutic Chemical (ATC) Classification System was used
to identify participants taking medications related to
mental illness [30]. This system classifies drugs into
groups according to system on which they act and their
therapeutic, pharmacological and chemical properties
[30]. ATC codes indicating mental illness include: anti-
depressants, psychostimulants, antipsychotics, anxiolytics,
hypnotics/sedatives and drugs for addictive disorders.
Participants were divided into two major groups; ‘mental
illness participants’ (those who reported use of ≥1 of the
medications associated with mental illness), and ‘non-
mental illness participants’ (no reported use of any medi-
cations associated with mental illness).
Baseline measures comprised demographic and
smoking-related variables, including nicotine depend-
ence [31], the Glover-Nilsson smoking behavioural
questionnaire [GN-SBQ] [32], motivation to quit
measured on a scale of 1–5 (where 1 is very low and
5 is very high), and stage of addiction measured using the
autonomy over smoking scale (AUTOS) [33]. The pri-
mary outcome was continuous smoking abstinence six
months after quit day, verified by an exhaled breath car-
bon monoxide measurement of <10 ppm using a Bedfont
Micro Smokerlyzer. Secondary outcomes included rate of
smoking relapse (date of return to regular daily smoking),
reduction in cigarettes smoked per day (CPD) in those
who did not quit, treatment compliance (continuing use
of treatment at three months), adverse events and accept-
ability measures (i.e. recommendation of product to
friend; stopping use of product due to dislike).
Analyses were performed using SAS version 9.3. All
tests were two-tailed, with significance set at 5%. Con-
tinuous outcomes were compared using t-tests, and bin-
ary outcomes were compared using chi-squared tests (or
Fisher’s Exact test if cell counts were <5). Primary out-
come analyses were undertaken on an intention-to-treat
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were assumed to be smoking. The primary outcome was
adjusted for mental illness status (as defined above)
using logistic regression.
Results
Overall 86 (13%) of the 657 participants reported
using ≥1 medication associated with mental illness
and 571 (87%) reported no such medication use. Of
the 86 mental illness participants, 39 were allocated
to 16 mg e-cigarettes, 35 to nicotine patches and 12
to 0 mg e-cigarettes. Three-quarters (74%, 64/86) re-
ported using antidepressants, 28% (24/86) antipsychotics,
14% (12/86) hypnotics/sedatives, 9% (8/86) anxiolytics,
and 1% (3/86) addictive disorder medications.
Participants categorised as having a mental illness had
a mean age of 44 years (SD = 12), mean smoking initi-
ation age of 15 years (SD = 4), 66% (57) were female, al-
most half (44%, 38) had <12 years school education and
half (43) had made a quit attempt in the previous year.
At baseline, participants with and without mental illness
were similar with respect to age, gender, education, pre-
vious quit attempts, behavioural dependence, motivation
to quit and stage of addiction . Compared to participants
without mental illness, those with mental illness were
less likely to be Māori (indigenous New Zealanders)
(8% [7/86] vs 36% [206/571, p < 0.001) or live with other
smokers (40% [34/86] vs 54% [308/571], p = 0.012), and
more likely to be nicotine dependent (mean Fagerstrom
score 6.3 versus 5.4, p < 0.0001; highly dependent
Fagerstrom score > 5: 70% vs 52%, p = 0.003) and smoke
more CPD (mean 19.4 vs 17.8 respectively, p = 0.049).
Baseline characteristics of participants with mental illness
by intervention are shown in Table 1.
Comparison of outcomes for participants with and
without mental illness
The pooled results across the three interventions for par-
ticipants with mental illness compared with those with-
out mental illness are shown in Table 2. No significantTable 1 Baseline characteristics of mental illness participants
Characteristic 21 mg nicotine patch (n =
Mean age 41 (11)
Female gender 69% (24)
Mean Fagerstrom score 6.5 (2.0)
Reported antidepressant use 69% (24)
Reported antipsychotic use 29% (10)
Reported anxiolytic use 6% (2)
Reported hypnosedative use 9% (3)
Reported drugs for addictive disorders use 3% (1)
Data are mean (SD) or % (n).difference between the two groups was noted, except for
a higher relapse rate in mental illness participants. The
primary outcome remained unchanged after adjusting
for mental illness. Forty-four adverse events occurred
amongst 35 mental illness participants compared with
248 events amongst 194 non-mental illness participants.
A single psychiatric adverse event occurred in the mental
illness group: a depressive episode that was not consid-
ered study-related. The only study-related adverse event
in this group was a sore throat in a person allocated
16 mg e-cigarettes.
Similar results were found when we analysed the data
by treatment allocation (Table 2). For participants allo-
cated to e-cigarettes there were no significant differences
in primary or secondary outcomes between those with
and without mental illness. The exception was smoking
relapse which occurred at a higher rate in mental illness
participants (Table 2). For participants allocated the
nicotine patch no significant differences in outcomes
were found between those with and without mental ill-
ness, with one exception: the six month quit rate was
higher in participants with mental illness compared to
those without mental illness (14% [5/35] vs 5% [12/260]
respectively, p = 0.038).
Comparison of interventions for mental illness participants
There were no significant differences in quit rates or re-
lapse rates for participants with mental illness randomised
to each of the three interventions (Table 3). Adverse event
counts relative to the number of participants were similar
(these were not subject to statistical testing due to small
numbers). No serious study-related adverse events were
noted in any group. For smoking reduction, compliance,
and acceptability 16 mg e-cigarettes outperformed nico-
tine patches. No significant difference was detected be-
tween 16 mg and 0 mg e-cigarettes for any outcome
tested. Among mental illness participants allocated 16 mg
e-cigarettes, approximately half (53%) liked their tactile,
cigarette-like qualities, sensory familiarity, perceived
health benefits, taste and ease of use.by intervention
35) 16 mg e-cigarette (n = 39) 0 mg e-cigarette (n = 12)
46 (11) 46 (14)
67% (26) 59% (7)
6.6 (1.7) 5.1 (2.4)
77% (30) 83% (10)
23% (9) 42% (5)
13% (5) 8% (1)
15% (6) 25% (3)
3% (1) 8% (1)
Table 2 Comparison of outcomes for participants with and without mental illness displaying both pooled and
intervention level results for the three interventions (21 mg nicotine patch, 16 mg e-cigarette, 0 mg e-cigarette)
Outcome Intervention Mental Illness (n = 86, 13%)
patch n = 35, 16 mg e-cigarette
n = 39, 0 mg e-cigarette n = 12
No Mental Illness (n = 571, 87%)
patch n = 260 , 16 mg e-cigarette




abstinence at six months % (n)
All interventions pooled 8% (7) 6% (34) 0.435
21 mg nicotine patch 14% (5) 5% (12) 0.038a
16 mg e-cigarette 5% (2) 7% (19) 0.750a
0 mg e-cigarette 0% (0) 5% (3) -
Relapse rate at six months % (n) All interventions pooled 79% (68) 67% (380) 0.020
21 mg nicotine patch 71% (25) 67% (175) 0.931
16 mg e-cigarette 85% (33) 66% (164) <0.0001
0 mg e-cigarette 83% (10) 67% (41) 0.239
Mean reduction in CPD from
baseline to six months in those
that did not quit Mean (SD)
All interventions pooled 7.7 (6.7) 8.4 (7) 0.508
21 mg nicotine patch 5.7 (6.3) 7.4 (7) 0.299
16 mg e-cigarette 9.9 (7) 9.4 (7.1) 0.743
0 mg e-cigarette 4.7 (3.5) 8.3 (5.9) 0.129b
Percentage reduction in CPD from
baseline to six months in those
that did not quit Mean (SD)
All interventions pooled 40% (30%) 46% (33%) 0.154
21 mg nicotine patch 29% (30%) 41% (35%) 0.147
16 mg e-cigarette 49% (28%) 51% (31%) 0.660
0 mg e-cigarette 31% (26%) 47% (28%) 0.245b
Treatment compliance at three
months % (n)
All interventions pooled 39% (30) 37% (167) 0.757
21 mg nicotine patch 20% (6) 18% (34) 0.752
16 mg e-cigarette 53% (19) 51% (107) 0.861
0 mg e-cigarette 46% (5) 54% (26) 0.741
Adverse events rate
(events/person month)
All interventions pooled 0.078 0.084 0.666 (IRR 0.93,
95% CI 0.68-1.28)
16 mg e-cigarette
and 0 mg e-cigarette
combined
0.05 0.05 0.592 (IRR 0.89,
95% CI 0.59-1.35)
Acceptability of intervention at
six months
‘Would recommend to a friend’ % (n) All interventions pooled 65% (49) 72% (313) 0.207
21 mg nicotine patch 37% (11) 63% (19) 0.122
16 mg e-cigarette 83% (30) 85% (175) 0.752
0 mg e-cigarette 80% (8) 89% (42) 0.594a
‘Stopped as didn’t like it ’% (n) All interventions pooled 34% (21/62) 32% (108/343) 0.711
21 mg nicotine patch 41% (12/29) 41% (169/169) 0.956
16 mg e-cigarette 29% (7/24) 23% (33/146) 0.482
0 mg e-cigarette 22% (2/9) 21% (6/28) 1.000a
CPD = cigarettes per day smoked, SD = standard deviation, IRR = Incidence rate ratio, CI = confidence interval, aFishers Exact test, bMann-Whitney test.
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Our findings suggest e-cigarettes could be a useful op-
tion for smoking cessation or harm reduction in smokers
with mental illness. Our finding that e-cigarettes may be
as effective, safe and acceptable for smoking cessation
and reduction in people with mental illness as in those
without is consistent with literature on standard cessa-
tion treatments in mental illness populations [2]. Thesefindings, when considered with the results of the main
ASCEND trial (which demonstrated non-inferiority of
e-cigarettes to NRT in a general population), also
suggest a possible role for e-cigarettes in smokers with
mental illness.
The absolute effectiveness of both NRT and e-cigarettes
was low for smokers with or without mental illness. More
intensive behavioural support would likely have improved
Table 3 Comparison of outcomes for mental illness participants who used 16 mg nicotine e-cigarettes, 0 mg
e-cigarettes and 21 mg nicotine patches
Outcome 21 mg nicotine patch
(n = 35, 40%)
16 mg nicotine e-cigarette
(n = 39, 45%)




abstinence at six months % (n)
14% (5) 5% (2) 0 0.245 (patch vs. 16 mg e-cig)a
- (16 mg vs. 0 mg e-cig)
0.115 (patch vs. combined e-cig)a
Relapse rate at six months % (n) 71% (25) 85% (33) 83% (10) 0.169 (patch vs. 16 mg e-cig)
1.000 (16 mg vs. 0 mg e-cig)
0.149 (patch vs. combined e-cig)
Mean reduction in CPD from
baseline to six months in those
that did not quit Mean (SD)
5.7 (6.3) 9.9 (7) 4.7 (3.5) 0.035 (patch vs. 16 mg e-cig)
0.068 (16 mg vs. 0 mg e-cig)
0.083 (patch vs. combined e-cig
Percentage reduction in CPD
from baseline to six months in
those that did not quit Mean (SD)
29% (30%) 49% (30%) 31% (30%) 0.025 (patch vs. 16 mg e-cig)
0.153 (16 mg vs. 0 mg e-cig)
0.049 (patch vs. combined e-cig)
Treatment compliance at
three months % (n)
20% (6) 53% (19) 46% (5) 0.006 (patch vs. 16 mg e-cig)
0.670 (16 mg vs. 0 mg e-cig)
0.006 (patch vs. combined e-cig)
Adverse events 17 (in 16 people) 22 (in 15 people) 5 (in 4 people) -
Acceptability of intervention at
six months
‘Would recommend to a friend’ % (n) 37% (11) 83% (30) 80% (8) <0.001 (patch vs. 16 mg e-cig)
1.000a (16 mg vs. 0 mg e-cig)
<0.001 (patch vs. combined e-cig)
‘Stopped as didn’t like it’ % (n) 41% (12/29) 29% (7/24) 22% (2/9) 0.356 (patch vs. 16 mg e-cig)
1.000a (16 mg vs. 0 mg e-cig)
0.242 (patch vs. combined e-cig)
CPD = cigarettes per day smoked, SD = standard deviation, aFishers Exact test.
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ple, and is an especially important component of treat-
ment for smokers with mental illness [34]. The extent
of smoking reduction among participants without men-
tal illness did not differ between treatments. However,
at six months smokers with mental illness who had
been allocated a nicotine e-cigarette smoked signifi-
cantly fewer cigarettes than those allocated to patch or
0 mg e-cigarette. This potential for harm reduction in
this population warrants further exploration, and aligns
with research recommendations from the UK’s National
Institute for Health and Clinical Excellence [35].
Among people with mental illness, e-cigarettes ap-
peared to have a similar safety profile to nicotine patch,
yet were generally more acceptable and associated with
greater compliance. These findings align with the gen-
eral population outcomes of the main trial. Many of the
observed advantages of e-cigarettes over patch were evi-
dent irrespective of whether nicotine was present, sug-
gesting that some of the benefit conferred is due to thetactile properties of the e-cigarette simulating the behav-
ioural and sensory aspects of smoking. The absence of
any difference between patch and e-cigarettes for quit
rates and relapse rates is difficult to interpret given the
small numbers. The reason for the higher quit rate ob-
served for patch users with mental illness compared to
those without is unknown, but may be a chance finding.
Limitations of the trial have been discussed in the ori-
ginal publication [21], including issues associated with
the e-cigarettes used in the trial (e.g. variable nicotine
content and delivery, and battery failure). Further limita-
tions specific to these analyses should also be acknowl-
edged, and indicate findings need to be interpreted with
caution and considered exploratory. First, the analyses
presented were of secondary data and post-hoc, and
multiple tests were undertaken thereby increasing the
chances of a type 1 error. Second, the analyses involved a
small sample size and therefore there was limited power
to detect subgroup differences. Finally, the generalisability
of the findings to the population of people with mental
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nosis of mental illness and the exclusion of people with
uncontrolled psychiatric or current chemical dependence
from the trial. It is possible that medication use was
under-reported, some mental illnesses may have been un-
diagnosed and therefore unmedicated, and some medica-
tions associated with mental illness could have been
prescribed instead for pain or sleep disorders. On balance
we believe our sample probably best represents those with
moderate mental illness, while excluding those with very
severe or milder (unmedicated) mental illness. It is also
possible that a small proportion taking medication for
pain or sleep disorders were wrongly classified as having
mental illness. In our study population 13% reported using
one or more mental health medications, whereas in a sur-
vey of 2,299 NZ smokers between 2007–09 20% had ever
had a mental illness diagnosis and 10% had a high prob-
ability of a depressive or anxiety disorder [36]. Notwith-
standing the prevalence of mental illness is likely to be
higher in more dependent smokers than the general popu-
lation of smokers, our findings align with population
estimates.
Conclusions
Our findings suggest e-cigarettes are similarly effective,
safe, and acceptable for smoking cessation and reduction
in people with mental illness as those without; further-
more among people with mental illness they appear to
be favoured over nicotine patches while yielding a
greater decrease in cigarette consumption. To improve
health outcomes in this priority group, new approaches
to cessation support and harm reduction are urgently
needed; our study suggests e-cigarettes warrant further
investigation in this regard.
Abbreviations
ATC: Anatomical Therapeutic Chemical; AUTOS: Autonomy over smoking
scale; E-cigarettes: Electronic cigarettes; GN-SBQ: Glover-Nilsson smoking
behavioural questionnaire; NRT: Nicotine replacement therapy; NZ: New
Zealand; RCT: Randomised controlled trial.
Competing interests
Funding for this study was provided by the Health Research Council of NZ
Grant (10–243); the Health Research Council had no further role in study
design; in the collection, analysis and interpretation of data; in the writing of
the report; or in the decision to submit the paper for publication. We declare
that we have received no support from any companies for the submitted
work and have no non-financial interests that might be relevant to the
submitted work. Chris Bullen has undertaken research on Ruyan e-cigarettes
funded by Health NZ, independently of Ruyan. Natalie Walker has provided
consultancy to the manufacturers of smoking cessation drugs, received
honoraria for speaking at a research meeting and received benefits in kind
and travel support from a manufacturer of smoking cessation drugs.
Authors’ contributions
CB and NW were PI and a co-investigator respectively on the ASCEND trial. BO
and OK-W designed this secondary analysis study. VP undertook the statistical
analyses for the original trial and the secondary analysis. This article was written
by BO with input from all co-authors. All authors contributed to and have
approved the final manuscript.Acknowledgements
The e-cigarettes and cartridges used in the ASCEND trial were Elusion brand
products provided by PGM International, NZ. PGM International had no role
in the study design, data collection, data analysis, data interpretation, or writing
of this report. We thank the participants, co-investigators on the original ASCEND
trial (C Howe, M Laugesen, H McRobbie, J Williman), research assistants, our
colleagues, the Health Research Council of NZ, PGM International, and NZ
Quitline. Natalie Walker is supported by a Heart Foundation Douglas Senior
Fellowship in Heart Health (Prevention).
Received: 22 September 2014 Accepted: 4 March 2015
References
1. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of
schizophrenia. Br J Psychiatry. 2000;177:212–7.
2. Banham L, Gilbody S. Smoking cessation in severe mental illness: what
works? Addiction. 2010;105(7):1176–89.
3. Campion J, Checinski K, Nurse J, McNeill A. Smoking by people with mental
illness and benefits of smoke-free mental health services. Adv Psychiatr
Treat. 2008;14:217–28.
4. Smith PH, Homish GG, Giovino GA, Kozlowski LT. Cigarette smoking and
mental illness: a study of nicotine withdrawal. Am J Public Health.
2014;104(2):e127–33. doi:10.2105/ajph.2013.301502.
5. Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the
US population. Tob Control. 2014;23(e2):e147–53. doi:10.1136/
tobaccocontrol-2013-051466.
6. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, et al.
Patterns of tobacco-related mortality among individuals diagnosed
with schizophrenia, bipolar disorder, or depression. J Psychiatr Res.
2014;48(1):102–10.
7. Centers for Disease Control and Prevention. Vital signs: Current cigarette
smoking among adults aged aged ≥ 18 Years—United States, 2009–2011.
MMWR Morb Mortal Wkly Rep. 2013;62(5):81–7.
8. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a
critical review and appraisal of 27 studies. Eur Neuropsychopharmacol.
2005;15:357–76.
9. McManus S, Meltzer H, Brugha T, Bebbington P, Jenkins R. Adult Psychiatric
Morbidity Survey 2007. Results of a household survey. The NHS Health &
Social Care Information Centre, Social Care Statistics; 2009. http://www.hscic.
gov.uk/catalogue/PUB02931/adul-psyc-morb-res-hou-sur-eng-2007-rep.pdf
10. McCreadie R, Kelly C. Patients with schizophrenia who smoke. Private
disaster, public resource. Br J Psychiatry. 2000;176:109.
11. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people
with mental illness: a review. Addiction. 2009;104(5):719–33.
12. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and
reduction in individuals with schizophrenia. Cochrane Database Syst Rev.
2013;2:CD007253. doi:10.1002/14651858.CD007253.pub3.
13. Pachas G, Cather C, Pratt S, Hoeppner B, Nino J, Carlini S, et al. Varenicline
for smoking cessation in schizophrenia: safety and effectiveness in a
12-week, open-label trial. J Dual Diagn. 2012;8(2):1178–125.
14. Rüther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, et al. EPA
Guidance on tobacco dependence and strategies for smoking cessation in
people with mental illness. Eur Psychiatry. 2014;29(2):65–82. http://dx.doi.
org/10.1016/j.eurpsy.2013.11.002.
15. van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation
interventions for smokers with current or past depression. Cochrane
Database Syst Rev. 2013;8:CD006102. doi:10.1002/14651858.CD006102.pub2.
16. Kishi T, Iwata N. Varenicline for smoking cessation in people with
schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry
Clin Neurosci. 2014. doi:10.1007/s00406-014-0551-3
17. Parker C, McNeill A, Ratschen E. Tailored tobacco dependence support for
mental health patients: a model for inpatient and community services.
Addiction. 2012;107 Suppl 2:18–25.
18. Royal College of Physicians. Smoking and Mental Health. London: RCP; 2013.
19. Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking
among adults with mental illness and association between mental health
treatment and smoking cessation. JAMA. 2014;311(2):172–82. doi:10.1001/
jama.2013.284985.
20. Caponnetto P, Campagna D, Cibella F, Morjaria J, Caruso M, Russo C, et al.
Efficiency and Safety of an electronic cigarette (ECLAT) as tobacco cigarettes
O’Brien et al. Tobacco Induced Diseases  (2015) 13:5 Page 7 of 7substitute: a prospective 12-month randomized control design study. PLoS
One. 2013;8(6):e66317. doi:10.1371/journal.pone.0066317.
21. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al.
Electronic cigarettes for smoking cessation: a randomised controlled
trial. Lancet. 2013;382(9905):1629–37. http://dx.doi.org/10.1016/S0140-
6736(13)61842-5.
22. Adriaens K, Van Gucht D, Declerck P, Baeyens F. Effectiveness of the
electronic cigarette: an eight-week flemish study with six-month follow-up
on smoking reduction, craving and experienced benefits and complaints.
Int J Environ Res Public Health. 2014;11(11):11220–48. doi:10.3390/
ijerph111111220.23.
23. Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R. Impact of an
electronic cigarette on smoking reduction and cessation in schizophrenic
smokers: a prospective 12-month pilot study. Int J Environ Res Public Health.
2013;10(2):446–61. http://dx.doi.org/10.3390/ijerph10020446.
24. Caponnetto P, Polosa R, Russo C, Leotta C, Campagna D. Successful
smoking cessation with electronic cigarettes in smokers with a documented
history of recurring relapses: a case series. J Med Case Rep. 2011;5:585.
25. Caponnetto P, Polosa R, Auditore R, Russo C, Campagna D. Smoking
cessation with e-cigarettes in smokers with a documented history of
depression and recurring relapses. Int J Clin Med. 2011;2:281–4.
26. Schneiderhan M. A case report of patient-initiated e-cigarette use and
resulting 5-months smoking cessation. J Pharm Pract. 2012;25(2):297.
27. Cummins SE, Zhu S-H, Tedeschi GJ, Gamst AC, Myers MG. Use of
e-cigarettes by individuals with mental health conditions. Tob Control.
2014;23 suppl 3:iii48–53. doi:10.1136/tobaccocontrol-2013-051511.
28. Prochaska JJ, Grana RA. E-Cigarette Use among Smokers with Serious Mental
Illness. PLoS One. 2014;9(11):e113013.
29. Bullen C, Williman J, Howe C, Laugesen M, McRobbie H, Parag V, et al.
Study protocol for a randomised controlled trial of electronic
cigarettes versus nicotine patch for smoking cessation. BMC Public
Health. 2013;13:210. doi:10.1186/471-2458-13-210.
30. WHO Collaborating Centre for Drug Statistics Methodology. ATC structure
and principles. 2011. [cited 2013 29/11/13]; Available from: http://www.
webcitation.org/6LTkY7A7C.
31. Heatherton T, Kozlowski L, Frecker R, Fagerstrom K. The fagerstrom test for
nicotine dependence: a revision of the fagerstrom tolerance questionnaire.
Br J Addict. 1991;86(9):1119–27.
32. Glover ED, Nilsson F, Westin A, Glover PN, Laflin MT, Persson B. Developmental
history of the Glover-Nilsson smoking behavioral questionnaire. Am J Health
Behav. 2005;29(5):443–55. doi:10.5555/ajhb.2005.29.5.443.
33. DiFranza JR, Wellman RJ, Ursprung WW, Sabiston C. The autonomy
over smoking scale. Psychol Addict Behav. 2009;23(4):656–65.
doi:10.1037/a0017439.
34. Hajek P. Electronic cigarettes for smoking cessation. Lancet. 2013.
http://dx.doi.org/10.1016/S0140-6736(13)61534-2.
35. NICE. National Institute for Health and Clinical Excellence (NICE). Tobacco:
harm-reduction approaches to smoking. PH45. 2013 01-Dec-2014; Available
from: https://www.nice.org.uk/guidance/ph45.
36. Wilson N, Weerasekera D, Collings S, Edwards R, Deen FS. Poorer mental
health in many New Zealand smokers: national survey data from the ITC
Project. N Z Med J. 2010;123(1326):129–32.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
